Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review

• Main Authors: N. A. Avxentyev (Author), I. I. Andreyashkina (Author), E. V. Artamonova (Author), L. V. Bolotina (Author), E. I. Kovalenko (Author), N. N. Sisigina (Author)
• Format: Book
• Published: ABV-press, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

At present, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors such as palbociclib, ribociclib, and abemaciclib are widely used for the first-line treatment of locally advanced or metastatic breast cancer. However, direct comparisons of these treatment options in randomized studies have not been co...